Shanghai SciBrunch Therapeutics Co., Ltd.
Shanghai SciBrunch Therapeutics Co., Ltd.
Explore linked clinical trials.1 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors | Advanced Solid Tumors; PARP Inhibitor | Recruiting | Phase 1 / Phase 2 | 2026-02-05 | NCT07359066 |